This study indicated that ALDOA, CCNA2, ANXA5 and CSK – which are key genes related to ITM – are lenvatinib targets, highlighting its potential use in postoperative anti-relapse therapy for ITM patients with HCC. This evidence concerns the gene ANXA5 and hepatocellular carcinoma.